Nanjing Medlander Medical Technology Co. Ltd. A (688273) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Nanjing Medlander Medical Technology Co. Ltd. A ¥16.99, price ¥30.07, upside -43.5%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Nanjing Medlander Medical Technology Co. Ltd. A for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
49‑month range ¥17.53 – ¥60.51 · fair‑value band ¥11.14 – ¥20.18 · the ¥30.07 price screens above the ¥16.99 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Follow Nanjing Medlander Medical Technology Co. Ltd. A in your weekly email
Every Wednesday you see whether Nanjing Medlander Medical Technology Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Nanjing Medlander Medical Technology Co.,Ltd. engages in the research and development, manufacture, sale, and service of pelvic floor rehabilitation equipment and related products in China and internationally.
Show more
Nanjing Medlander Medical Technology Co.,Ltd. engages in the research and development, manufacture, sale, and service of pelvic floor rehabilitation equipment and related products in China and internationally. It offers pelvic floor and obstetrics and gynecology rehabilitation, reproductive rehabilitation and anti-aging product, and sports rehabilitation products, as well as consumables and IT products, such as vaginal electrodes, rectal electrodes, and vaginal probes. The company also provides electronic colposcopes, biofeedback stimulation devices, high-frequency electrocautery devices, ultrasonic uterine involution devices, and electro-ultrasound therapy devices; and finger joint rehabilitation assessment systems, portable hand function rehabilitation assessment systems, hand function magnetic stimulation systems, transcranial magnetic stimulation systems, biofeedback devices, and portable biofeedback devices. In addition, it provides pelvic floor muscle rehabilitation devices and power recliner. It serves clients in gynecology, obstetrics, rehabilitation, proctology, postpartum recovery centers, and urology areas. The company was founded in 2013 and is headquartered in Nanjing, China.
Stock analysis
Nanjing Medlander Medical Technology Co. Ltd. A (688273) currently trades at ¥30.07, while our model-based Fair Value estimate is ¥16.99, implying the stock looks roughly 77.0% overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ¥21.11 per share, and 0 of the 16 models we run sit above the ¥30.07 price.
Bear case: the Asset-Based group reads lowest at ¥9.01, and 16 of the 16 models stay below the price. Evidence for this calculation is high.
Scenario range: ¥11.14 (bear) to ¥20.18 (bull), the price of ¥30.07 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Nanjing Medlander Medical Technology Co. Ltd. A reported revenue of 432M CNY in FY2025 versus 342M CNY in FY2021, a compound +6.0%/yr. Reported net income was 103M CNY in FY2025, compounding −3.5%/yr from FY2021.
Key figures
Market cap 3.0B CNY (≈ $449M) · P/E ratio 34.6 · P/S ratio 8.22 · EPS (TTM) ¥0.8700 · Dividend yield 2.7% · Net margin 23.8% · Return on equity 6.0% · Return on assets (EBIT) 10.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 50% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −44%, 688273 screens richer than that median.
Fair Value models
Bear ¥11.14Fair Value ¥16.99Bull ¥20.18
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (¥0.0512 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.36/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+1.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.1%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−5.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−8.5%
Dividend (yield on the price)2.7%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.40% → 24%
Compare Nanjing Medlander Medical Technology Co. Ltd. A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 358 stocks
Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score58 · Above median
Fair Value upside−44% · Below median
Profitability
Return on equity (TTM)6% · Above median
Return on assets3% · Above median
Net margin (TTM)21% · Top 25%
Operating margin (TTM)24% · Top 25%
Growth and dividend
Revenue growth−16% · Bottom 25%
Dividend yield (TTM)2.7% · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (TTM)34.6× · Pricier than median
P/B2.26× · Pricier than median
P/S (TTM)7.37× · Priciest 25%
EV/EBITDA25.6× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 4
FUTURE (revenue growth)0· sector 31
PAST (return on equity)24· sector 7
HEALTH (low debt)0· sector 97
DIVIDEND (yield)53· sector 38
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Nanjing Medlander Medical Technology Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/688273
Frequently asked questions
Is Nanjing Medlander Medical Technology Co. Ltd. A (688273) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of ¥16.99 versus a price of ¥30.07, about −44% upside (overvalued).
What is the fair value of 688273?
Our model-based fair value for Nanjing Medlander Medical Technology Co. Ltd. A is ¥16.99 (as of Sep 23, 2026), built from audited fundamentals. The current price: ¥30.07.
What is the quality score of 688273?
Nanjing Medlander Medical Technology Co. Ltd. A has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
Our model-based price target is the fair value of ¥16.99 (as of Sep 23, 2026) from 16 valuation models. Cautious scenario ¥11.14, optimistic scenario ¥20.18. It is a calculation from audited fundamentals, not an analyst target.
What is the Nanjing Medlander Medical Technology Co. Ltd. A stock forecast for 2026?
Our models put fair value at ¥16.99, about −44% upside versus a price of ¥30.07 (overvalued). Cautious scenario ¥11.14, optimistic scenario ¥20.18. The calculation is refreshed regularly with new filings.
What is the revenue of Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
Nanjing Medlander Medical Technology Co. Ltd. A reported trailing-twelve-month revenue of about 413M CNY (latest available figure, as of Sep 23, 2026).
Does Nanjing Medlander Medical Technology Co. Ltd. A pay a dividend?
Nanjing Medlander Medical Technology Co. Ltd. A currently shows a dividend yield of about 2.66% relative to its recent price (as of Sep 23, 2026).
What is the intrinsic value of Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nanjing Medlander Medical Technology Co. Ltd. A it is ¥16.99 per share (as of Sep 23, 2026), against a price of ¥30.07. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Nanjing Medlander Medical Technology Co. Ltd. A stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 688273 trades above its calculated fair value: price ¥30.07, fair value ¥16.99, a gap of about −44% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688273?
No. The price is what the market pays today (¥30.07); the fair value is what the company's own numbers justify (¥16.99). For Nanjing Medlander Medical Technology Co. Ltd. A the two are ¥13.08 per share apart. That gap is exactly why we show both numbers side by side.
How much is Nanjing Medlander Medical Technology Co. Ltd. A worth?
The market values Nanjing Medlander Medical Technology Co. Ltd. A at about 3.0B CNY (market capitalisation, as of Sep 23, 2026). Per share that is ¥30.07; our models calculate a fair value of ¥16.99 per share.
What do the bullish and bearish scenarios say about 688273?
Our models span a range for Nanjing Medlander Medical Technology Co. Ltd. A: cautious scenario ¥11.14, base ¥16.99, optimistic ¥20.18 per share (as of Sep 23, 2026, price ¥30.07). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688273?
Nanjing Medlander Medical Technology Co. Ltd. A trades at a price-to-earnings ratio of 34.6 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥16.99 is built from several models across several years. Other multiples: P/B 2.3, P/S 7.4, EV/EBITDA 25.6.
How solid is the balance sheet of Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
Balance-sheet figures for Nanjing Medlander Medical Technology Co. Ltd. A (as of Sep 23, 2026): return on equity 6.0%. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is 688273 from its 52-week high?
Nanjing Medlander Medical Technology Co. Ltd. A trades at ¥30.07, about 50% below its 52-week high of ¥60.51 and 13% above the low of ¥26.64 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of ¥16.99 is for.
Which stocks are comparable to Nanjing Medlander Medical Technology Co. Ltd. A?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nanjing Medlander Medical Technology Co. Ltd. A stock attractive at the current price?
The data as of Sep 23, 2026: price ¥30.07, calculated fair value ¥16.99 (−44%), Quality Score 58/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688273 calculated?
We run Nanjing Medlander Medical Technology Co. Ltd. A through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥16.99, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Nanjing Medlander Medical Technology Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
The closing price on Sep 23, 2026 was ¥30.07. Our model-based fair value is ¥16.99, about −44% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nanjing Medlander Medical Technology Co. Ltd. A right now?
The price sits above even our optimistic bull case (¥20.18). The favourable scenario is already priced in. Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (¥11.14 to ¥20.18) leaves room in how you read the outcome.
Key figures of Nanjing Medlander Medical Technology Co. Ltd. A
How large is the market capitalisation of Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
The market capitalisation of Nanjing Medlander Medical Technology Co. Ltd. A is 3.0B CNY (≈ $449M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
The price-to-sales ratio of Nanjing Medlander Medical Technology Co. Ltd. A is 8.22 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
Earnings per share at Nanjing Medlander Medical Technology Co. Ltd. A are ¥0.8700 (price ÷ EPS = P/E 34.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
The dividend yield of Nanjing Medlander Medical Technology Co. Ltd. A is 2.7% (payout 92.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
The net margin of Nanjing Medlander Medical Technology Co. Ltd. A is 23.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
The return on equity (ROE) of Nanjing Medlander Medical Technology Co. Ltd. A is 6.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
On an EBIT basis the return on assets of Nanjing Medlander Medical Technology Co. Ltd. A is 10.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
The operating margin of Nanjing Medlander Medical Technology Co. Ltd. A is 24.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
Revenue at Nanjing Medlander Medical Technology Co. Ltd. A is growing −16.1% versus a year earlier (3y avg +4.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Nanjing Medlander Medical Technology Co. Ltd. A (688273)?
Earnings per share at Nanjing Medlander Medical Technology Co. Ltd. A are growing −42.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Nanjing Medlander Medical Technology Co. Ltd. A (688273) generate?
The free cash flow of Nanjing Medlander Medical Technology Co. Ltd. A is −12.7M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch Nanjing Medlander Medical Technology Co. Ltd. A in the live analysis
One click puts Nanjing Medlander Medical Technology Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
